Physician profile
Danielle Werge
NPI 1437607793
$27,229.35
in general payments reported to CMS, 2019-2025
30 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,677 · 2022: $4,088 · 2023: $1,408 · 2024: $5,450 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,321 · Food and Beverage: $5,542 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,721 · Travel and Lodging: $781 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,321.24 |
| Food and Beverage | $5,542.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,721.20 |
| Travel and Lodging | $780.78 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $7,814.28 | 2021-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $4,011.04 | 2022-2025 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $3,748.48 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Biocryst Pharmaceuticals, INC. | $3,228.78 | 2024-2025 | Orladeyo |
| Pharming Healthcare, INC. | $2,924.32 | 2021-2025 | Ruconest |
| Pfizer INC. | $1,460.21 | 2021-2023 | |
| Amgen INC. | $972.97 | 2021-2025 | Tezspire |
| Genzyme Corporation | $972.66 | 2021-2025 | |
| Glaxosmithkline, LLC. | $567.82 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $324.09 | 2021-2025 | |
| Leo Pharma INC. | $224.43 | 2022-2023 | Adbry |
| Optinose US, INC. | $204.76 | 2021-2022 | |
| Csl Behring | $144.26 | 2022-2025 | Haegarda, Hizentra, Andembry |
| Adma Biomanufacturing LLC | $72.39 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $65.12 | 2024-2025 | Xolair |
| Incyte Corporation | $52.04 | 2023-2025 | Opzelura |
| Kaleo, INC. | $50.48 | 2022-2023 | Auvi-Q |
| Grifols USA, LLC | $47.94 | 2023-2024 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.09 | 2021-2022 | |
| Inspire Medical Systems, INC. | $36.06 | 2025 | Inspire |
| Ars Pharmaceuticals Operations, INC. | $35.54 | 2025 | Neffy |
| Lilly USA, LLC | $29.42 | 2024 | Ebglyss |
| Viatris Specialty LLC | $25.39 | 2025 | Yupelri |
| Mylan Specialty L.P. | $23.70 | 2023 | Yupelri |
| Blueprint Medicines Corporation | $23.33 | 2023 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $17.12 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.36 | 2025 | Takhzyro |
| Galderma Laboratories, L.P. | $15.11 | 2025 | Nemluvio |
| Alk-Abello, INC | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Werge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.